CTOs on the Move

Washington Regional Transplant Consortium

www.wrtc.org

 
Washington Regional Transplant Consortium is a Annandale, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.wrtc.org
  • 7619 Little River Tpke Ste 900
    Annandale, VA USA 22003
  • Phone: 703.641.0100

Executives

Name Title Contact Details

Similar Companies

Barton HealthCare System

The Barton HealthCare System provides a variety of excellent medical services for patients, employees, visitors and the community.

Premier Health Partners

Premier Health Partners is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

API WELLNESS CENTER

API WELLNESS CENTER is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CliniComp

CliniComp is a global provider of Electronic Health Record (EHR) software and solutions that has enjoyed an unrivaled track record of performance and reliability in the most complex high acuity hospital environments for decades. Starting in 2014 CliniComp EHR extends the scope of coverage to Outpatient and Ancillaries such as Pharmacy, Radiology, and clinical laboratory information systems. This fully-integrated one stop expanded offering guarantees seamless CPOE and order/results management as well as transparent patient record viewing across all patient environments, distinct sites and time. Every Patient. Everywhere. For Life. The CCI system is certified for Stage 2 Meaningful Use and is currently supported internationally.

Heart Force Medical

Heart Force Medical Inc. (HFM), a private company, has invented and has patents pending for the digital Ballistocardiograph (dBG(TM)). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). This movement (acceleration and force) is sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM's proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.